Loading clinical trials...

Tyrosine Allergoid Paediatric and Adult Study | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Tyrosine Allergoid Paediatric and Adult Study

A Long-term, Prospective, Open, Multi-centre, Non-interventional Study to Evaluate the Effectiveness After Treatment With TA Bäume Top (Trees) and TA Gräser Top (Grass) Following a Perennial Posology in Children and Adults, as Well as Proofing the Non-inferiority of Children Compared to Adults

NCT05186025•Allergy Therapeutics

View on ClinicalTrials.gov

Summary

The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial posology.

Eligibility

Age

5 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients from 5 years of age who are treated with TA Gräser top or TA Bäume top due to rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, which are caused by an IgE-mediated allergy to grass and rye pollen or birch, alder and hazel pollen according to the respective SmPC.
•Patients will only be included in this study after the decision on the treatment has been made.

Exclusion Criteria

•History of allergen-specific immunotherapy (SIT) for trees or grass within the last 5 years
•If it´s intended to treat the patient with only a preseasonal therapy
•A patient should also not be included in the presence of any of the conditions listed in the respective SmPC

Locations (1)

Universitätsklinikum Augsburg

Augsburg, Germany

Key Dates

Start Date

November 6, 2020

Primary Completion Date

June 1, 2026

Completion Date

October 1, 2026

Last Updated

January 30, 2026

Enrollment

320

ACTUAL participants

Conditions

Allergic Rhinitis Due to PollenAllergic ConjunctivitisAllergic Asthma

Interventions

MATA trees or MATA grass

DRUG

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

NCT05008965

Allergic Asthma

View study

RECRUITINGPHASE3

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

NCT04699604

Allergic Asthma

View study

ENROLLING_BY_INVITATIONEARLY_PHASE1

Asthma Inflammation Research

NCT01536522

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 30, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Tyrosine Allergoid Paediatric and Adult Study

Inclusion Criteria

Exclusion Criteria

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

Asthma Inflammation Research

The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis

Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

Trial of JYB1904 in Patients With Allergic Asthma